Get all your news in one place.
100's of premium titles.
One app.
Start reading
Medical Daily
Medical Daily
Cole Mercer

Pancreatic Cancer Patients No Longer Need Expanded Access to Get a RAS Inhibitor After Federal Approval

Approval Replaces a Case-by-Case Access Route

The Food and Drug Administration has approved daraxonrasib, sold as Rasonque, for adults with metastatic pancreatic adenocarcinoma, making a drug that patients could previously obtain only through clinical trials or a compassionate use program available for prescribing by treating oncologists.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.